These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 3895919)

  • 21. Influences of protein levels on the cerebrospinal fluid distribution of ceftazidime & ceftriaxone in the cerebrospinal fluid of patients with inflamed meningitis.
    Ichinose N; Yoshikawa G; Fukao E; Takahata T; Ichisawa M; Enoki Y; Taguchi K; Oda T; Tsutsumi K; Matsumoto K
    J Infect Chemother; 2022 Aug; 28(8):1216-1219. PubMed ID: 35513971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Third generation cephalosporins.
    Donowitz GR
    Infect Dis Clin North Am; 1989 Sep; 3(3):595-612. PubMed ID: 2671141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Rational parameters in the treatment of bacterial meningitis with modern cephalosporins].
    Brückner O; Trautmann M
    Infection; 1987; 15 Suppl 4():S214-9. PubMed ID: 3312038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Susceptibility of 324 nonfermentative gram-negative rods to 6 cephalosporins and azthreonam.
    Appelbaum PC; Tamim J; Pankuch GA; Aber RC
    Chemotherapy; 1983; 29(5):337-44. PubMed ID: 6311492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of third-generation cephalosporins in the treatment of bacterial meningitis.
    Modai J
    Chemioterapia; 1986 Oct; 5(5):313-8. PubMed ID: 3791477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
    Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
    Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime.
    Adu A; Armour CL
    Drugs; 1995 Sep; 50(3):423-39. PubMed ID: 8521766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Animal models as predictors of outcome of therapy with broad spectrum cephalosporins.
    Rouse MS; Tallan BM; Henry NK; Steckelberg JM; Wilson WR
    J Antimicrob Chemother; 1992 Apr; 29 Suppl A():39-45. PubMed ID: 1601755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical applications of a new parenteral antibiotic in the treatment of severe bacterial infections.
    Holloway WJ; Palmer D
    Am J Med; 1996 Jun; 100(6A):52S-59S. PubMed ID: 8678098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Third-generation cephalosporins.
    Klein NC; Cunha BA
    Med Clin North Am; 1995 Jul; 79(4):705-19. PubMed ID: 7791418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
    Jones RN; Barry AL; Thornsberry C; Gerlach EH; Fuchs PC; Gavan TL; Sommers HM
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of third-generation cephalosporin resistance on adult in-hospital mortality from post-neurosurgical bacterial meningitis.
    Chang CJ; Ye JJ; Yang CC; Huang PY; Chiang PC; Lee MH
    J Microbiol Immunol Infect; 2010 Aug; 43(4):301-9. PubMed ID: 20688290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cefepime: overview of activity in vitro and in vivo.
    Grassi GG; Grassi C
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():87-94. PubMed ID: 8150771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections.
    Plosker GL; Foster RH; Benfield P
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 1):91-106. PubMed ID: 10175990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of gram-negative bacillary meningitis: role of the new cephalosporin antibiotics.
    Cherubin CE; Corrado ML; Nair SR; Gombert ME; Landesman S; Humbert G
    Rev Infect Dis; 1982; 4 Suppl():S453-64. PubMed ID: 6294799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The in-vivo antibacterial activity of ceftazidime (Gr 20263)--a comparison with other new beta-lactam antibiotics and gentamicin.
    Acred P; Ryan DM; Sowa MA; Watts CM
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():247-55. PubMed ID: 19802994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An in-vitro comparison of new cephalosporins with special reference to Pseudomonas aeruginosa.
    van Klingeren B
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():97-105. PubMed ID: 19810171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo activity of ceftriaxone (Ro 13-9904), a new broad-spectrum semisynthetic cephalosporin.
    Beskid G; Christenson JG; Cleeland R; DeLorenzo W; Trown PW
    Antimicrob Agents Chemother; 1981 Aug; 20(2):159-67. PubMed ID: 6269487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and bacteriologic efficacy of moxalactam, cefotaxime, cefoperazone, and rocephin in experimental bacterial meningitis.
    Schaad UB; McCracken GH; Loock CA; Thomas ML
    J Infect Dis; 1981 Feb; 143(2):156-63. PubMed ID: 6260870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.